Quick Dispatch:
Your surmount 2 tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount 2 tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ships.
Need Help?
Questions about surmount 2 tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount 2 tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial in your area.
SURMOUNT-1 Trial
27.33
SURMOUNT-2: Tirzepatide achieved up to 15.7% weight loss
21.43
Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial | Diabetes Therapy
25.55
Is Mounjaro Gliding Toward an Obesity Approval?
25.36
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity
24.80
Tirzepatide Achieves Mean Weight Loss of 15.7% in SURMOUNT-2 Trial
25.21
00377-2/asset/984f48c3-9a91-4eba-8a7d-d724f5e65288/main.assets/gr2_lrg.jpg "Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial")
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
20.29
